ABCL Insider Trading | AbCellera Biologics Buys and Sells

ABCL Insider Trading

Insider Ownership Percentage: 28.00%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00

AbCellera Biologics Insider Trading History Chart

This chart shows the insider buying and selling history at AbCellera Biologics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$10M-$5M$0$5M$10MTotal Insider BuyingTotal Insider Selling

AbCellera Biologics Share Price & Price History

Current Price: $2.22
Price Change: Price Increase of +0.13 (6.22%)
As of 04/2/2025 05:00 PM ET

This chart shows the closing price history over time for ABCL up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MayJunJulAugSepOctNovDecJanFebMar$2.09Closing price on 04/01/25:

AbCellera Biologics Insider Trading History

See Full Table

SEC Filings (Institutional Ownership Changes) for AbCellera Biologics (NASDAQ:ABCL)

61.42% of AbCellera Biologics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at ABCL by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$33Mbought$12MsoldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$20M$0$20MTotal InflowsTotal Outflows
AbCellera Biologics logo
AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
Read More on AbCellera Biologics

Today's Range

Now: $2.22
Low: $2.02
High: $2.24

50 Day Range

MA: $2.82
Low: $2.09
High: $3.53

52 Week Range

Now: $2.22
Low: $2.03
High: $4.75

Volume

4,065,564 shs

Average Volume

2,442,812 shs

Market Capitalization

$661.53 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.45

Who are the company insiders with the largest holdings of AbCellera Biologics?

AbCellera Biologics' top insider shareholders include:
  1. Holdings Ltd Thermopylae (Major Shareholder)
  2. Andrew Booth (CFO)
Learn More about top insider investors at AbCellera Biologics.